529 Million People Living With Diabetes Worldwide in 2021
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, June 23, 2023 -- The prevalence of diabetes is increasing and is projected to affect more than 1.31 billion people by 2050, according to a study published online June 22 in The Lancet.
Kanyin Liane Ong, Ph.D., from the University of Washington in Seattle, and colleagues projected diabetes prevalence through 2050 using estimates of diabetes prevalence and burden from 1990 to 2021, computed in 204 countries and territories.
The researchers found 529 million people were living with diabetes worldwide in 2021, and the global age-standardized total diabetes prevalence was 6.1 percent. The highest age-standardized rates were seen in North Africa and the Middle East (9.3 percent) at the super-region level and in Oceania (12.3 percent) at the regional level. Nationally, the world's highest age-specific prevalence of diabetes was in Qatar, at 76.1 percent among adults aged 75 to 79 years. Total diabetes prevalence mainly reflects type 2 diabetes, which accounted for 96.0 percent of diabetes cases and 95.4 percent of diabetes disability-adjusted life years (DALYs) worldwide in 2021. Of global type 2 diabetes DALYs, 52.2 percent were attributable to high body mass index (BMI) in 2021. Between 1990 and 2021, the contribution of high BMI to type 2 diabetes DALYs increased by 24.3 percent. More than 1.31 billion people are projected to have diabetes by 2050; 43.6 percent of 204 countries and territories will have an age-standardized rate greater than 10 percent by 2050.
"Our estimates should also serve as a rallying call to galvanize increased research funding to identify and develop more effective measures to prevent diabetes," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.